Pubblicazioni

CASTELLI R, GALLIPOLI P, SCHIAVON R, TEATINI T, LAMBERTENGHI DELILIERS G, BERGAMASCHINI L.
“INCREASED RISK OF HEPARIN INDUCED THROMBOCYTOPENIA AND THROMBOSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA CARRYING THE HOMOZYGOUS JAK2 V617F MUTATION”

J Thromb Thrombolysis 2019;47(1):155-156

MAFFIOLI M, ORLANDI E , PASSAMONTI F.
“CHRONIC MYELOPROLIFERATIVE NEOPLASMS IN THE ELDERLY”

Eur J Int Med 2018;58:33-42

MORA B, GIORGINO T, GUGLIELMELLI P, ET AL.
“PHENOTYPE VARIABILITY OF PATIENTS WITH POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IS ASSOCIATED WITH THE TIME TO PROGRESSION FROM POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA”

Leuk Res 2018;69:100-102

MORA B, GIORGINO T, GUGLIELMELLI P, ET AL.
“VALUE OF CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY OF THE MYSEC PROJECT”

Haematologica 2018;103:e392

TEFFERI A, MUDIREDDY M, MANNELLI F, ET AL.
“BLAST PHASE MYELOPROLIFERATIVE NEOPLASM: MAYO-AGIMM STUDY OF 410 PATIENTS FROM TWO SEPARATE COHORTS”

Leukemia 2018;32(5):1200-1210

PASSAMONTI F, MAFFIOLI M.
“THE ROLE OF JAK2 INHIBITORS IN MPNs 7 YEARS AFTER APPROVAL”

Blood 2018;131(22):2426-2435

MERLI M, FRIGENI M, ALRIC L, ET AL.
“DIRECT ACTING ANTIVIRALS IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS”

The Oncologist 2018;23(10):1-10

BARRACO D, MORA B, GUGLIELMELLI P, ET AL.
“GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS OF THE MYSEC PROJECT”

Blood Cancer J 2018;8(10):89

CASTELLI R, GALLIPOLI P, SCHIAVON R, TEATINI T, LAMBERTENGHI DELILIERS G, BERGAMASCHINI L.
“HIGH PREVALENCE OF HEPARIN INDUCED THROMBOCYTOPENIA WITH THROMBOSIS AMONG PATIENTS WITH ESSENTIAL THROMBOCYTEMIA CARRYING V617F MUTATION”

J Thromb Thrombolysis 2018;45(1):106-113.

CASTELLI R, SCHIAVON R, LAMBERTENGHI DELILIERS G.
“THE IMPACT OF ANAEMIA, TRANSFUSIONE DEPENDENCY, COMORBIDITIES AND POLYPHARMACY IN ELDERLY PATIENTS WITH LOW.-RISK MYELODYSPLASTIC SYNDROMES”

J Med Oncol 2018;35(3):33.

CASTELLI R, BERGAMASCHINI L, LAMBERTENGHI DELILIERS G.
“FIRST-LINE TREATMENT WITH BENDAMUSTINE AND RITUXIMAB, IN PATIENTS WITH INTERMEDIATE-/HIGH-RISK SPLENIC MARGINAL ZONE LYMPHOMAS”

J Med Oncol 2018;35(2):15.

PASSAMONTI F, MAFFIOLI M, MORA B.
“THERAPY OF POLYCYTHEMIA VERA: IT IS TIME TO CHANGE?”

Oncotarget 2017;8(61):102759-102760.

CASTELLI R, BERGAMASCHINI L, SCHIAVON R, LAMBERTENGHI DELILIERS G.
“PERSONALIZED TREATMENT STRATEGIES FOR ELDERLY PATIENTS WITH MYELODYSPLASTIC SYNDROMES”

J Expert Rev Hematol. 2017;10(12):1077-1086.

MAFFIOLI M, MORA B, PASSAMONTI F.
“POLYCYTHEMIA VERA: FROM NEW, MODIFIED DIAGNOSTIC CRITERIA TO NEW THERAPEUTIC APPROACHES”

J Clin Adv Hematol Oncol 2017;15(9):700-707.

ANNALORO C, AIRAGHI L, MOMETTO G, MAIRA D.
“SINDROME METABOLICA”

Ematologia Oncologica.it 2017, Anno 4, N.1.

KROEGER N, IACOBELLI S, NIEDERWIESER D, PLATZBECKER U, UDDIN R, HUEBEL K, ET AL.
“DOSE-REDUCED VERSUS STANDARD CONDITIONING FOLLOWED BY ALLOGENEIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME: A PROSPECTIVE RANDOMIZED PHASE III STUDY OF THE EBMT (RICMAC-TRIAL)”

J Clin Oncol 2017 Jul 1;35(19):2157-2164.

PASSAMONTI F, GIORGINO T, MORA B, GUGLIELMELLI P, RUMI E, ET AL.
“A CLINICAL-MOLECULAR PROGNOSTIC MODEL TO PREDICT SURVIVAL IN PATIENTS WITH POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS”

Leukemia 2017;31(12):2726-2731.

PASSAMONTI F, MORA B, GIORGINO T, GUGLIELMELLI P, CAZZOLA M, MAFFIOLI M, ET AL.
“DRIVER MUTATIONS’ EFFECT IN SECONDARY MYELOFIBROSIS: AN INTERNATIONAL MULTICENTER STUDY BASED ON 781 PATIENTS.”

Leukemia 2017;31(4):970-973.

CASTELLI R, SCIARA S, LAMBERTENGHI DELILIERS G, PANTALEO G.
“BIOSIMILAR EPOETIN ALFA INCREASES HAEMOGLIBIN LEVELS AND BRINGS COGNITIVE AND SOCIO-RELATIONAL BENEFITS TO ELDERLY TRANSFUSION-DEPENDENT MULTIPLE MYELOMA PATIENTS: RSULTS FROM A PILOT STUDY.”

Ann Hematol 2017;96(5):779-786.

CASTELLI R, FERRARIS L, PANTALEO G, LAMBERTENGHI DELILIERS G, CICARDI M.
“HIGH RATE OF HEPATITIS B VIRAL BREAKTHROUGH IN ELDERLY NON-HODGKIN LYMPHOMAS PATIENTS TREATED WITH RITUXIMAB BASED CHEMOTHERAPY.”

Digestive and Liver Disease 2016;48:1394–97.

CASTELLI R, GIDARO A, LAMBERTENGHI DELILIERS G.
“BENDAMUSTINE AND RITUXIMAB, AS FIRST LINE TREATMENT, IN INTERMEDIATE, HIGH RISK SPLENIC MARGINAL ZONE LYMPHOMAS OF ELDERLY PATIENTS.”

Mediterranean Journal of Hematology and Infectious Diseases 2016;8:1-5.

GIDARO A, LAMBERTENGHI DELILIERS G, GALLIPOLI P, ARQUATI M, WU MA, CASTELLI R.
“LABORATORY AND CLINICAL RISK ASSESSMENT TO THREAT MYELODYSPLASTIC SYNDROMES.”

Clinical Chemistry and Laboratory Medicine 2016;54:1411-1426.

LAMBERTENGHI DELILIERS G, ANNALORO C.
“ALTERAZIONI QUANTITATIVE E QUALITATIVE DEI LEUCOCITI.”

In: Manuale di Ematologia-Edizioni Minerva Medica (II edizione ) Capitolo 7°, pp 77-89, 2015.

CASTELLI R, PANTALEO G, GALLIPOLI P, GIDARO A, ARQUATI M, WU MA, LAMBERTENGHI DELILIERS G.
“SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MYLTIPLE MYELOMA.”

Anti-Cancer Drugs 2015, 26:1078–1082.

CASTELLI R, DELILIERS GL, COLOMBO R, MOREO G, GALLIPOLI P, PANTALEO G.
BIOSIMILAR EPOETIN IN ELDERLY PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES IMPROVES ANEMIA, QUALITY OF LIFE, AND BRAIN FUNCTION.

Ann Hematol. 2014 Sep;93(9):1523-9.

Commenti chiusi